|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| A61K 38/00 |
| (11) | Number of the document | 3060252 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14855074.2 |
| Date of filing the European patent application | 2014-10-21 | |
| (97) | Date of publication of the European application | 2016-08-31 |
| (45) | Date of publication and mention of the grant of the patent | 2019-12-11 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/061592 |
| Date | 2014-10-21 |
| (87) | Number | WO 2015/061330 |
| Date | 2015-04-30 |
| (30) | Number | Date | Country code |
| 201361893814 P | 2013-10-21 | US | |
| 201461979384 P | 2014-04-14 | US | |
| 201462012805 P | 2014-06-16 | US |
| (72) |
SMITH, Ernest S., US
ZAUDERER, Maurice, US
BOWERS, William J., US
JONASON, Alan, US
|
| (73) |
Vaccinex, Inc.,
1895 Mt. Hope Avenue, Rochester, NY 14620,
US
|
| (54) | USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS |
| USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS |